Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: Report of a case with long-term follow-up

Hematological Oncology

Volumn 31, Issue 4, 2013, Pages 213-217

  Fabbri, Alberto ^a   Cencini, Emanuele ^a   Pietrini, Alice ^a   Gozzetti, Alessandro ^a   Defina, Marzia ^a   Fontanelli, Giulia ^b   Mazzei, Maria Antonietta ^a   Volterrani, Luca ^a   Bocchia, Monica ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

AITL; Chemorefractory; Lenalidomide; Salvage treatment

Indexed keywords

ACETYLSALICYLIC ACID; BILIRUBIN; CD4 ANTIGEN; COTRIMOXAZOLE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; HAPTOGLOBIN; HEMOGLOBIN; IFOSFAMIDE; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; LENALIDOMIDE; NAVELBINE; OXALIPLATIN; PREDNISONE; STEROID; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; VIRUS DNA;

ADULT; ANEMIA; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; AXILLARY LYMPH NODE; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; BONE MARROW BIOPSY; BONE MARROW METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CD4+ T LYMPHOCYTE; CERVICAL LYMPHADENOPATHY; COMPUTER ASSISTED TOMOGRAPHY; COOMBS TEST; DISEASE ASSOCIATION; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; FATIGUE; FOLLOW UP; GENERALIZED LYMPHADENOPATHY; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HOSPITAL ADMISSION; HUMAN; HYPERGAMMAGLOBULINEMIA; HYPERURICEMIA; IMMUNE DYSREGULATION; INGUINAL LYMPH NODE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOCYTOSIS; LONG TERM CARE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOCYTIC INFILTRATION; MAINTENANCE CHEMOTHERAPY; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT REFERRAL; PHYSICAL EXAMINATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; RETICULOCYTE COUNT; SPLENOMEGALY; T LYMPHOCYTE; THROMBOCYTE COUNT; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

AITL; CHEMOREFRACTORY; LENALIDOMIDE; SALVAGE TREATMENT;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYTARABINE; DEOXYCYTIDINE; DEXAMETHASONE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; IMMUNOLOGIC FACTORS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; PREDNISONE; REMISSION INDUCTION; SALVAGE THERAPY; THALIDOMIDE; VINBLASTINE;

EID: 84889088256     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2038     Document Type: Article

References (25)

1. Rüdiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13: 140-149.
2. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011; 117: 6756-6767.
3. Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2008.
4. Willenbrock K, Brauninger A, Hansmann ML. Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol 2007; 138: 733-739.
5. Weiss LM, Jaffe ES, Liu XF, Chen YY, Shibata D, Medeiros LJ. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 1992; 79: 1789-1795.
6. Alizadeh AA, Advani RH. Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategy. Clin Adv Hematol Oncol 2008; 6: 899-909.
7. Mourad N, Mounier N, Briere J, et al. Clinical, biologic and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated with the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008; 111: 4463-4470.
8. Vallet S, Witzens-Harig M, Jaeger D, Podar K. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Expert Opin Pharmacother 2012; 13(4): 473-494.
9. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by 2 distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380-386.
10. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006; 108: 618-621.
11. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signalling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525-4530.
12. Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003; 17: 41-44.
13. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4952-4957.
14. Dueck G, Chua N, Prasad A, et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010; 116: 4541-4548.
15. Zinzani PL, Pellegrini C, Broccoli A, et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma 2011; 52: 1585-1588.
16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
17. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012; 30: 631-636.
18. d'Amore F, Radford J, Relander T, et al. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 2010; 150(5): 565-573.
19. Dang NH, Fayad L, McLaughlin P, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007; 136: 439-447.
20. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29: 1182-1189.
21. Advani R, Horwitz S, Zelenetz A, Horning SJ. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 2007; 48: 521-525.
22. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007; 109: 4952-4963.
23. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627.
24. Zelenetz AD, Abramson JS, Advani RH, et al. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2011; 9(5): 484-560.
25. de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 2009; 148: 673-689.